Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies

Cancer

Volumn 118, Issue 6, 2012, Pages 1523-1532

  Loupakis, Fotios ^a,b   Cremolini, Chiara ^a,b   Salvatore, Lisa ^a,b   Schirripa, Marta ^a,b   Lonardi, Sara ^c   Vaccaro, Vanja ^d   Cuppone, Federica ^d   Giannarelli, Diana ^d   Zagonel, Vittorina ^c   Cognetti, Francesco ^d   Tortora, Giampaolo ^e   Falcone, Alfredo ^a,b   Bria, Emilio ^d  

^a Azienda Ospedaliero Universitaria Pisana   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF VERONA   (Italy)

Author keywords

cetuximab; chemotherapy; colorectal cancer; meta analysis; panitumumab

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; MUTANT; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; WILD TYPE;

ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REGRESSION ANALYSIS;

EID: 84857993465     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26460     Document Type: Article

References (41)

1. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010; 375: 1030-1047.
2. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27: 2091-2096.
3. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O,. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009; 14: 22-28.
4. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005; 97: 981-989. (Pubitemid 41430564)
5. Jubb AM, Harris AL,. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010; 11: 1172-1183.
6. Grothey A,. EGFR antibodies in colorectal cancer: where do they belong? J Clin Oncol. 2010; 28: 4668-4670.
7. Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z,. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis. 2009; 24: 677-685.
8. Welch S, Spithoff K, Rumble RB, Maroun J,. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010; 21: 1152-1162.
9. Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S,. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev. 2009;(3): CD005392.
10. Loupakis F, Bria E, Vaccaro V, et al. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res. 2010; 29: 58.
11. Van Cutsem E, Nordlinger B, Cervantes A,. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol. 2010; 21 (suppl 5): v93-v97.
12. Pignon JP, Hill C,. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol. 2001; 2: 475-482. (Pubitemid 33586302)
13. Bria E, Gralla RJ, Raftopoulos H, et al. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer. 2009; 63: 50-57.
14. Higgins JPT, Green S,. Cochrane Handbook for Systematic Reviews of Intervention 4.2.6 [updated September 2006]. The Cochrane Library. Vol 4. Chichester, UK: John Wiley & Sons; 2006.
15. Parmar MK, Torri V, Stewart L,. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998; 17: 2815-2834. (Pubitemid 28562978)
16. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR,. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16.
17. Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R,. Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002; 7: 181-187. (Pubitemid 34651220)
18. Altman DG,. Confidence intervals for the number needed to treat. BMJ. 1998; 317: 1309-1312. (Pubitemid 28502420)
19. Djulbegovic B, Soares HP, Kumar A,. What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. Cancer Treat Rev. 2006; 32: 572-576. (Pubitemid 44464135)
20. Soares HP, Kumar A, Djulbegovic B,. Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev. 2007; 33: 87-89. (Pubitemid 46132003)
21. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR,. Introduction to Meta-Analysis. Chichester, UK: John Wiley & Sons; 2009.
22. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009; 27: 663-671.
23. Van Cutsem E, Kohne CH, Hitre EZJ, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-1417.
24. Van Cutsem E, Rougier P, Kohne CH, Stroh C, Schlichting M, Bokemeyer C,. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): results according to KRAS and BRAF mutation status [abstract]. Eur J Cancer. 2009; 7 (suppl): 345. Abstract P-6077.
25. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28: 4697-4705.
26. Maughan T, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomized superiority trial (MRC COIN) [abstract]. Eur J Cancer. 2009; 7 (suppl): 4. Abstract 6LBA.
27. Tveit K, Guren T, Glimelius P, et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. Ann Oncol. 2010; 21 (suppl 8): LBA20.
28. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009; 27: 672-680.
29. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009; 360: 563-572.
30. Borner M, Koeberle D, Von Moos R, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol. 2008; 19: 1288-1292. (Pubitemid 351911959)
31. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A,. Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol. 2010; 7: 309-317.
32. Piessevaux H, Schlichting M, Heeger S, Van Cutsem E, Tejpar S,. Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (mCRC): analysis from the CRYSTAL study [abstract]. Ann Oncol. 2010; 21 (suppl 8). Abstract 596P.
33. Arnold D, Hinke AC, Reinacher-Schick AC, et al. Waterfall plot analysis of XELOX or XELIRI with cetuximab or bevacizumab in patients with advanced colorectal cancer (ACRC): combined analysis of 2 randomized first-line phase II trials of the AIO CRC study group [abstract]. J Clin Oncol. 2008; 26 (suppl). Abstract 4067.
34. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006; 24: 2065-2072. (Pubitemid 46622116)
35. Scoggins CR, Campbell ML, Landry CS, et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol. 2009; 16: 35-41.
36. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26: 5705-5712.
37. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009; 101: 715-721.
38. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-762.
39. Kris MG, Benowitz SI, Adams S, et al. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2010; 28: 5327-5347.
40. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304: 1812-1820.
41. Tejpar S, Bokemeyer C, Celik I, Schlichting M, Sartorius U, Van Cutsem E,. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab [abstract]. J Clin Oncol. 2011; 29 (suppl). Abstract 3511.